Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BHV-8555
- Development stage
- Preclinical
- Lead developer
- Biohaven
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
BHV-8555 is an investigational, brain-penetrant, orally available small molecule designed to prevent alpha-synuclein aggregation. Developed by Biohaven, the compound is being advanced as a potential disease-modifying therapy for Parkinson's disease. By targeting the aggregation of alpha-synuclein, a key pathological hallmark of Parkinson's disease and other synucleinopathies, BHV-8555 aims to mitigate neurodegeneration and slow disease progression. It is currently in early-stage development under Biohaven's discovery engine.
02
Targets
SNCA (Alpha-synuclein)
Beyond the preview
Go deeper on BHV-8555.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BHV-8555.